Antineoplastic Agents, Alkylating

"Antineoplastic Agents, Alkylating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)

Descriptor ID	D018906
MeSH Number(s)	D27.505.519.124.035 D27.505.954.248.150 D27.888.569.035.035
Concept/Terms	Antineoplastic Agents, Alkylating Antineoplastic Agents, Alkylating Alkylating Antineoplastic Agents Alkylating Antineoplastic Drugs Alkylating Antineoplastics Antineoplastic Alkylating Agents Antineoplastic Drugs, Alkylating Antineoplastics, Alkylating Alkylating Agents, Antineoplastic Alkylating Drugs, Antineoplastic Antineoplastic Alkylating Drugs Drugs, Antineoplastic Alkylating

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Alkylating".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Alkylating Agents [D27.505.519.124]
Antineoplastic Agents, Alkylating [D27.505.519.124.035]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antineoplastic Agents, Alkylating [D27.505.954.248.150]
Toxic Actions [D27.888]
Noxae [D27.888.569]
Alkylating Agents [D27.888.569.035]
Antineoplastic Agents, Alkylating [D27.888.569.035.035]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Agents, Alkylating".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Alkylating".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents, Alkylating" by people in this website by year, and whether "Antineoplastic Agents, Alkylating" was a major or minor topic of these publications.

Bar chart showing 28 publications over 13 distinct years, with a maximum of 4 publications in 2012

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
2000	0	1	1
2003	1	0	1
2006	1	1	2
2010	2	1	3
2012	2	2	4
2014	1	2	3
2015	2	1	3
2016	2	1	3
2017	0	1	1
2018	2	0	2
2020	1	2	3
2025	1	0	1

Below are the most recent publications written about "Antineoplastic Agents, Alkylating" by people in Profiles.

Balis FM, Rieger E, Bunin NJ, Gardiner J, Shaw LM, Olson TS, Milone MC. New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis. Cancer Chemother Pharmacol. 2025 Feb 11; 95(1):32.

View in: PubMed
Das A, Alshareef M, Porto GBF, Infinger LK, Vandergrift WA, Lindhorst SM, Varma AK, Patel SJ, Cachia D. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment. J Neurol Sci. 2020 Nov 15; 418:117102.

View in: PubMed
Wolf GT, Liu S, Bellile E, Sartor M, Rozek L, Thomas D, Nguyen A, Zarins K, McHugh JB. Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial. Oral Oncol. 2020 12; 111:104928.

View in: PubMed
Das A, Henderson FC, Alshareef M, Porto GBF, Kanginakudru I, Infinger LK, Vandergrift WA, Lindhorst SM, Varma AK, Patel SJ, Cachia D. MGMT-inhibitor in combination with TGF-?RI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. Clin Transl Oncol. 2021 Mar; 23(3):612-619.

View in: PubMed
Ward SM, Skinner M, Saha B, Emrick T. Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma. Mol Pharm. 2018 11 05; 15(11):5263-5276.

View in: PubMed
Ali AN, Zhang P, Yung WKA, Chen Y, Movsas B, Urtasun RC, Jones CU, Choi KN, Michalski JM, Fischbach AJ, Markoe AM, Schultz CJ, Penas-Prado M, Garg MK, Hartford AC, Kim HE, Won M, Curran WJ. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol. 2018 Mar; 137(1):39-47.

View in: PubMed
Cai YS, Sarotti AM, G?ndisch D, Kondratyuk TP, Pezzuto JM, Turkson J, Cao S. Heliotropiumides A and B, new phenolamides with N-carbamoyl putrescine moiety from Heliotropium foertherianum collected in Hawaii and their biological activities. Bioorg Med Chem Lett. 2017 10 15; 27(20):4630-4634.

View in: PubMed
Voorhees PM, Usmani SZ. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy. Clin Adv Hematol Oncol. 2016 Sep; 14(9):719-28.

View in: PubMed
Kamiya-Matsuoka C, Cachia D, Waguespack SG, Crane CH, Mahajan A, Brown PD, Nam JY, McCutcheon IE, Penas-Prado M. Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma. Pituitary. 2016 Aug; 19(4):415-21.

View in: PubMed
Strickland BA, Cachia D, Jalali A, Cykowski MD, Penas-Prado M, Langford LA, Li J, Shah K, Weinberg JS. Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report. Neurosurgery. 2016 Mar; 78(3):E466-73.

View in: PubMed

People

Explore

Similar Concepts

Top Journals